News Sentiment

TARS sentiment intelligence

Tarsus Pharmaceuticals Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 58 Balanced news tone 57 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 59.85 Week of 17 Jul 2026
Weighted tone 58/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

78/100 classification confidence.

Company focus 48

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

+2.9% over one week, -5.2% over four weeks, trend inactive, and materially above fair value.

Latest direct headline Neutral

TARS Stock Drops After Culper Research Accuses Tarsus Of Illegal Medicare Copay Scheme

Market Reaction

Balanced read

67/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 78/100 classification
One-week reaction 2.9% Price confirming higher
Trend fit Trend inactive -5.2% over four weeks
Fair value 34.7% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 23
Neutral 26
Negative 8

Relevance

Why the article matched

Direct first
Direct company coverage 48
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
Stock Titan 9
Moomoo 4
TradingView 4
simplywall.st 4
VisionMonday.com 2
Orange County Business Journal 2
GuruFocus 2

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 13
Deals and strategy 9
Analyst action 4
Regulatory and legal 3

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 57
The Globe and Mail Direct company coverage

Analysts Offer Insights on Healthcare Companies: UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS)

Analysts have provided new ratings for UnitedHealth (UNH) and Tarsus Pharmaceuticals (TARS) in the Healthcare sector. TD Cowen maintained a Hold rating on UnitedHealth with a $430.00 price target, while Mizuho Securities maintained a Buy rating on Tarsus Pharmaceuticals with a $1

Tone
Positive 73/100
Event
Analyst action
Published
15 Jul 2026 11:40
Source
The Globe and Mail
VisionMonday.com Direct company coverage

Tarsus Pharmaceuticals Announces Executive Leadership Transition

Tarsus Pharmaceuticals has announced a leadership transition where Neera Clase, previously senior vice president of market access, will serve as interim chief commercial officer. This follows the departure of Aziz Mottiwala, who is leaving to become CEO of a public medical device

Tone
Positive 76/100
Event
Market update
Published
15 Jul 2026 04:19
Source
VisionMonday.com
Orange County Business Journal Direct company coverage

Tarsus Chief Commercial Officer Departs

Tarsus Pharmaceuticals Inc. announced that its Chief Commercial Officer, Aziz Mottiwala, is departing to become the CEO of an unnamed publicly traded medical device company. Neera Clase, previously SVP of market access, will serve as interim CCO. Following the announcement, share

Tone
Negative 30/100
Event
Market update
Published
14 Jul 2026 17:11
Source
Orange County Business Journal
Stock Titan Direct company coverage

Top Tarsus commercial executive departs as eye drug XDEMVY gains traction

Tarsus Pharmaceuticals announced that Chief Commercial Officer Aziz Mottiwala has left the company to become CEO of a public medical device company. Neera Clase, formerly Senior Vice President of Market Access, has been appointed Interim Chief Commercial Officer. This leadership

Tone
Negative 38/100
Event
Market update
Published
14 Jul 2026 12:10
Source
Stock Titan
Moomoo Direct company coverage

Press Release: Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Tarsus Pharmaceuticals announced a significant executive leadership transition as the company prepares for its next phase of growth, following the anticipated FDA approval of XDEMVY and its commercial launch. Wendy White is departing from her role as Chief Commercial Officer to p

Tone
Positive 72/100
Event
Regulatory and legal
Published
14 Jul 2026 11:40
Source
Moomoo
Stock Titan Direct company coverage

[8-K] Tarsus Pharmaceuticals, Inc. Reports Material Event

Tarsus Pharmaceuticals, Inc. (TARS) announced a material event via an 8-K filing, reporting a leadership change within its commercial organization. Aziz Mottiwala, the Chief Commercial Officer, will depart the company on July 15, 2026, to become the Chief Executive Officer of a p

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 20:41
Source
Stock Titan
Yahoo! Finance Canada Direct company coverage

Tarsus Pharmaceuticals Announces Executive Leadership Transition as Company Advances Next Phase of Growth

Tarsus Pharmaceuticals announced an executive leadership transition as Chief Commercial Officer Aziz Mottiwala departs to become CEO of a public medical device company. Neera Clase, previously Senior Vice President of Market Access, has been appointed Interim Chief Commercial Off

Tone
Positive 67/100
Event
Market update
Published
13 Jul 2026 19:41
Source
Yahoo! Finance Canada
TradingView Direct company coverage

Tarsus Pharmaceuticals Enters Retina Market With iRenix Deal, Adds IRX-101 to Pipeline

Tarsus Pharmaceuticals has acquired iRenix Medical, integrating IRX-101, a late-stage ocular surface antiseptic, into its pipeline to expand into the retina market. IRX-101 aims to improve the experience for patients undergoing intravitreal injections by offering a better alterna

Tone
Positive 72/100
Event
Deals and strategy
Published
11 Jul 2026 14:11
Source
TradingView
Stock Traders Daily Direct company coverage

How Tarsus Pharmaceuticals Inc. (TARS) Affects Rotational Strategy Timing

This article analyzes Tarsus Pharmaceuticals Inc. (TARS) using AI models to provide trading strategies. It highlights strong sentiment across all horizons for TARS, suggesting an overweight bias with an exceptional risk-reward short setup. The analysis includes position, momentum

Tone
Positive 76/100
Event
Market update
Published
10 Jul 2026 06:16
Source
Stock Traders Daily
VisionMonday.com Direct company coverage

Tarsus Pharmaceuticals Acquires iRenix Medical, Developer of Late-Stage Ocular Antiseptic IRX-101

Tarsus Pharmaceuticals has acquired iRenix Medical, gaining control of IRX-101, an investigational ocular antiseptic designed to reduce post-procedural pain and corneal toxicity in patients receiving intravitreal therapy. The acquisition involved an upfront payment of approximate

Tone
Positive 73/100
Event
Deals and strategy
Published
10 Jul 2026 04:39
Source
VisionMonday.com
Orange County Business Journal Direct company coverage

Tarsus Pharmaceuticals Acquires iRenix for $75M

Tarsus Pharmaceuticals has acquired iRenix Medical Inc. for $75 million, adding the late-stage ocular antiseptic candidate IRX-101 to its portfolio. IRX-101 is designed to improve post-procedural pain and corneal toxicity in patients undergoing intravitreal therapy, building on T

Tone
Negative 37/100
Event
Market update
Published
09 Jul 2026 17:46
Source
Orange County Business Journal
Moomoo Direct company coverage

Tarsus Pharmaceuticals Buys IRenix Medical

This article announces that Tarsus Pharmaceuticals has acquired IRenix Medical. The acquisition suggests Tarsus is expanding its portfolio or capabilities, potentially in the medical device or biotechnology space given IRenix Medical's name. Further details would clarify the stra

Tone
Positive 71/100
Event
Deals and strategy
Published
09 Jul 2026 10:11
Source
Moomoo
Market source Direct company coverage

All You Need to Know About Tarsus Pharmaceuticals (TARS) Rating Upgrade to Buy

Tarsus Pharmaceuticals (TARS) has received a rating upgrade to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This improvement in the company's earnings outlook is expected to favorably impact its stock price, as changes in future earnings potential are s

Tone
Positive 75/100
Event
Analyst action
Published
09 Jul 2026 09:41
Source
Market source
GuruFocus Direct company coverage

Tarsus Pharmaceuticals (TARS) Acquires iRenix Medical for $75M

Tarsus Pharmaceuticals has acquired iRenix Medical for $75 million in upfront payments (cash and stock), plus potential milestone payments up to $490 million, to expand its eye care portfolio with investigational therapy IRX-101. Despite this strategic move and strong financial s

Tone
Negative 41/100
Event
Regulatory and legal
Published
09 Jul 2026 09:41
Source
GuruFocus
Quartr Direct company coverage

Tarsus Pharmaceuticals (TARS) Q3 2024 earnings summary

Tarsus Pharmaceuticals reported record Q3 2024 results with $48.1M in XDEMVY net product sales, an 18% sequential increase. The company expanded payer coverage to over 80% of covered lives, increased its sales force, and launched a direct-to-consumer TV campaign. Financial highli

Tone
Positive 80/100
Event
Earnings
Published
09 Jul 2026 06:46
Source
Quartr
Quartr Direct company coverage

Tarsus Pharmaceuticals (TARS) M&A announcement Summary

Tarsus Pharmaceuticals announced an M&A deal to expand into the retina segment, aiming to address unmet needs in ocular surface antiseptics with its IRX-101 product. The acquisition involves an upfront payment of $75 million, with potential milestones up to $490 million and tiere

Tone
Positive 81/100
Event
Deals and strategy
Published
09 Jul 2026 02:41
Source
Quartr
Investing.com Direct company coverage

Tarsus Pharmaceuticals acquires iRenix for $75 million upfront

Tarsus Pharmaceuticals has acquired iRenix Medical for an initial $75 million, consisting of cash and stock. The deal includes potential milestone payments up to $490 million for iRenix's investigational ocular antiseptic, IRX-101. This acquisition is significant as IRX-101 showe

Tone
Positive 74/100
Event
Deals and strategy
Published
08 Jul 2026 22:41
Source
Investing.com
Moomoo Direct company coverage

Press Release: Tarsus Advances Eye Care Leadership Strategy With Acquisition of IRenix Medical and Late-Stage Asset IRX-101

Tarsus Pharmaceuticals, Inc. has announced the acquisition of IRenix Medical and its late-stage asset IRX-101, a topical ophthalmic lotilaner solution for dry eye disease. This strategic move aims to strengthen Tarsus's leadership in eye care, leveraging their existing expertise

Tone
Positive 71/100
Event
Deals and strategy
Published
08 Jul 2026 21:46
Source
Moomoo
GuruFocus Direct company coverage

TARS Acquires iRenix Medical for $75M in a Strategic Move

Tarsus Pharmaceuticals Inc (TARS) is acquiring iRenix Medical for an initial $75 million, split equally between cash and Tarsus common stock, with potential milestone payments up to $490 million. This strategic acquisition aims to enhance Tarsus's ophthalmic therapeutic portfolio

Tone
Negative 40/100
Event
Deals and strategy
Published
08 Jul 2026 21:03
Source
GuruFocus
Stock Titan Direct company coverage

Tarsus (NASDAQ: TARS) acquires iRenix, adds late-stage IRX-101 eye asset

Tarsus Pharmaceuticals has acquired iRenix Medical for an upfront consideration of approximately $75 million, including cash and stock, plus up to $490 million in potential milestone payments. This acquisition adds IRX-101, a late-stage ocular antiseptic, to Tarsus's pipeline, ai

Tone
Positive 71/100
Event
Deals and strategy
Published
08 Jul 2026 20:40
Source
Stock Titan
TradingView Direct company coverage

Tarsus Pharmaceuticals Acquires iRenix With $37.5M Cash, Stock; Milestones Up to $490M

Tarsus Pharmaceuticals has acquired iRenix Medical for $37.5 million in cash and 607,093 Tarsus common shares. The deal, which closed on July 6, 2026, includes potential payments of up to $490 million in regulatory and commercial milestones and low-to-mid single-digit revenue sha

Tone
Positive 75/100
Event
Earnings
Published
08 Jul 2026 20:39
Source
TradingView
GlobeNewswire Direct company coverage

Tarsus Advances Eye Care Leadership Strategy with Acquisition of iRenix Medical and Late-Stage Asset IRX-101

Tarsus Pharmaceuticals has acquired iRenix Medical, gaining IRX-101, an investigational ocular antiseptic aimed at reducing pain and corneal toxicity from intravitreal injections. This acquisition reinforces Tarsus's leadership in eye care, building on positive Phase 2b/3 trial d

Tone
Positive 72/100
Event
Deals and strategy
Published
08 Jul 2026 19:41
Source
GlobeNewswire